Medicenna Granted U.S. Patent Number 11,680,090 Titled 'Interleukin-2 Fusion Proteins and Uses Thereof'
Portfolio Pulse from Benzinga Newsdesk
Medicenna Therapeutics Corp. has been granted U.S. Patent No. 11,680,090 for a method that enhances immune cell survival and proliferation, potentially improving the fitness of cancer-fighting immune cells.
August 01, 2023 | 3:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Medicenna Therapeutics Corp. has secured a U.S. Patent for a method that could improve the effectiveness of cancer-fighting immune cells. This could potentially lead to the development of new treatments.
The granting of a patent to Medicenna Therapeutics Corp. is a significant event as it provides the company with exclusive rights to a method that could potentially enhance the effectiveness of cancer-fighting immune cells. This could lead to the development of new treatments, which would be a positive development for the company and could potentially boost its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100